Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006093 · ClinicalTrials.gov registry record · Phase 1
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Study locations
NCT00006093: Completed Phase 1 study of Brain and Central Nervous System Tumors, sponsored by New Approaches to Brain Tumor Therapy Consortium.
NCT00006093 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by New Approaches to Brain Tumor Therapy Consortium. The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006093, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10
- Study locations
Study Summary
RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who have progressive or recurrent malignant glioma.
Conditions Studied
Interventions
- DRUG cilengitide
Study Locations (10)
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Emory University Hospital - Atlanta - Atlanta
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Michigan
- Henry Ford Hospital - Detroit
North Carolina
- Comprehensive Cancer Center at Wake Forest University - Winston-Salem
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-09 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
What the finished NCT00006093 record still lists
NCT00006093 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which cilengitide is the first listed.
NCT00006093 lists 10 locations in 10 states (Alabama, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT00006093 about?
NCT00006093 is a clinical study titled "EMD 121974 in Treating Patients With Progressive or Recurrent Glioma". RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who have progressive or recurrent malignant glioma.
What is the current status of trial NCT00006093?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-09. Estimated completion is 2006-10.
What conditions does trial NCT00006093 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00006093?
The interventions under investigation include: cilengitide (DRUG).
Who is sponsoring clinical trial NCT00006093?
This trial is sponsored by New Approaches to Brain Tumor Therapy Consortium, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006093 being conducted?
This trial has 10 study locations across Alabama, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia